BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

BioNTech and Bristol Myers Squibb announced a collaboration to co-develop the bispecific antibody BNT327 for solid tumors.

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

Bristol Myers Squibb (NYSE:BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ:BNTX) immunotherapy bispecific antibody BNT327 for solid tumors. The candidate ...

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types ...

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types ...

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types ...